REG - BkofA Merrill Lynch AbbVie Inc. - Form 38.5(a) - AbbVie Inc

AbbvieAnnouncement

04/05/2020 11:55

RNS Number : 8138L
  
Bank of America Merrill Lynch
  
04 May 2020
  
 


FORM 38.5(a)
 
IRISH TAKEOVER PANEL



DISCLOSURE UNDER RULE 38.5(a) OF THE IRISH TAKEOVER PANEL ACT, 1997,

TAKEOVER RULES, 2013



DEALINGS BY CONNECTED EXEMPT PRINCIPAL TRADERS WITH RECOGNISED

INTERMEDIARY STATUS AND DEALING IN A CLIENT-SERVING CAPACITY 
 




1.


KEY INFORMATION










Name of exempt principal trader: 






Merrill Lynch International







Company dealt in 






AbbVie Inc







Class of relevant security to which the

dealings being disclosed relate(Note 1) 






Common - US00287Y1091







Date of dealing 






01/05/2020



 




2.


DEALINGS (Note 2)









(a)


Purchases and sales







Total number of relevant securities acquired


Highest price paid (Note 3)


Lowest price paid (Note 3)




N/A


N/A


N/A



 



Total number of securities disposed


Highest price received (Note 3)


Lowest price received (Note 3)




3,650


83.21 USD


82.38 USD



 




(b)


Derivatives transactions (other than options transactions)








Product name,

e.g. CFD 


Nature of transaction

(Note 4)


Number of relevant securities
(Note 5)


Price per unit

(Note 3)




Swaps


Opening a Long Position


492


82.203 USD



 




(c)


Options transactions in respect of existing relevant securities








(i)


Writing, selling, purchasing or varying







Product name, e.g. call option


Writing, selling, purchasing, varying etc.


Number of securities to which the option relates (Note 5)


Exercise price


Type, e.g. American, European etc


Expiry date


Option money paid/ received per unit (Note 3)




N/A


N/A


N/A


N/A


N/A


N/A


N/A



 




(ii)


Exercising








Product name,

e.g. call option 


Number of securities


Exercise price per

unit (Note 3)




N/A


N/A


N/A



 




3.


OTHER INFORMATION




 




Agreements, arrangements or understandings relating to options or derivatives




 



Full details of any agreement, arrangement or understanding between the person 

disclosing and any other person relating to the voting rights of any relevant 

securities under any option referred to on this form or relating to the voting rights 

or future acquisition or disposal of any relevant securities to which any derivative 

referred to on this form is referenced. If none, this should be stated. 




None







 



Date of disclosure


04/05/2020




Contact name


Tolu Tade




Telephone number


+44207 996 3410




Name of offeree/offerer with 

which connected 


AbbVie Inc




Nature of connection(Note 6) 


Advisor to - AbbVie Inc



 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
  END
 
 
ISEFIFSAETISIII